Ciba Vision/QLT Visudyne Will Have Average Annual Cost of $4,175/Patient
Executive Summary
Ciba Vision/QLT PhotoTherapeutics' Visudyne will have an average cost of $4,175.20 per patient, based on a price to doctors of $1,228 per vial, and an average of 3.4 treatments per patient per year.
You may also be interested in...
Novartis, CMS Continue To Talk On Visudyne Macular Degeneration Coverage
Novartis and the Centers for Medicare & Medicaid Services will be meeting right up until the deadline for expanded coverage for Novartis/QLT's Visudyne
Novartis, CMS Continue To Talk On Visudyne Macular Degeneration Coverage
Novartis and the Centers for Medicare & Medicaid Services will be meeting right up until the deadline for expanded coverage for Novartis/QLT's Visudyne
Novartis/QLT Visudyne Expanded Indications Cover Up To 250,000 Patients
The approval of Novartis/QLT's Visudyne (verteporfin) for use in pathologic myopia and presumed ocular histoplasmosis could double the labeled patient population for the ophthalmic agent.